Literature DB >> 30064973

Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.

Elodie Pronier1,2, Robert L Bowman1,2, Jihae Ahn1,2, Jacob Glass1,2, Cyriac Kandoth1,2,3,4, Tiffany R Merlinsky1,2, Justin T Whitfield1,2, Benjamin H Durham1, Antoine Gruet2, Amritha Varshini Hanasoge Somasundara1,2, Raajit Rampal1,2, Ari Melnick5, Richard P Koche2, Barry S Taylor1,2,3,4, Ross L Levine1,2,5,6,7.   

Abstract

Genetic studies have identified recurrent somatic mutations in acute myeloid leukemia (AML) patients, including in the Wilms' tumor 1 (WT1) gene. The molecular mechanisms by which WT1 mutations contribute to leukemogenesis have not yet been fully elucidated. We investigated the role of Wt1 gene dosage in steady-state and pathologic hematopoiesis. Wt1 heterozygous loss enhanced stem cell self-renewal in an age-dependent manner, which increased stem cell function over time and resulted in age-dependent leukemic transformation. Wt1-haploinsufficient leukemias were characterized by progressive genetic and epigenetic alterations, including those in known leukemia-associated alleles, demonstrating a requirement for additional events to promote hematopoietic transformation. Consistent with this observation, we found that Wt1 depletion cooperates with Flt3-ITD mutation to induce fully penetrant AML. Our studies provide insight into mechanisms of Wt1-loss leukemogenesis and into the evolutionary events required to induce transformation of Wt1-haploinsufficient stem/progenitor cells.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30064973      PMCID: PMC6148447          DOI: 10.1182/blood-2018-03-837468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

2.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

3.  Loss of heterozygosity of the Wilms' tumor suppressor gene (WT1) in in situ and invasive breast carcinoma.

Authors:  A Fabre; A H McCann; D O'Shea; D Broderick; G Keating; B Tobin; T Gorey; P A Dervan
Journal:  Hum Pathol       Date:  1999-06       Impact factor: 3.466

4.  The Wilms tumor suppressor gene wt1 is required for development of the spleen.

Authors:  U Herzer; A Crocoll; D Barton; N Howells; C Englert
Journal:  Curr Biol       Date:  1999 Jul 29-Aug 12       Impact factor: 10.834

5.  WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.

Authors:  Yiping Wang; Mengtao Xiao; Xiufei Chen; Leilei Chen; Yanping Xu; Lei Lv; Pu Wang; Hui Yang; Shenghong Ma; Huaipeng Lin; Bo Jiao; Ruibao Ren; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Mol Cell       Date:  2015-01-15       Impact factor: 17.970

6.  Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.

Authors:  Aline Renneville; Nicolas Boissel; Virginie Zurawski; Laura Llopis; Valéria Biggio; Olivier Nibourel; Nathalie Philippe; Xavier Thomas; Hervé Dombret; Claude Preudhomme
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

7.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors:  Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

8.  Expression of the Wilms' tumor gene (WT1) in human leukemias.

Authors:  H Miwa; M Beran; G F Saunders
Journal:  Leukemia       Date:  1992-05       Impact factor: 11.528

9.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.

Authors:  Adam J Mead; Wen Hao Neo; Nikolaos Barkas; Sahoko Matsuoka; Alice Giustacchini; Raffaella Facchini; Supat Thongjuea; Lauren Jamieson; Christopher A G Booth; Nicholas Fordham; Cristina Di Genua; Deborah Atkinson; Onima Chowdhury; Emmanouela Repapi; Nicki Gray; Shabnam Kharazi; Sally-Ann Clark; Tiphaine Bouriez; Petter Woll; Toshio Suda; Claus Nerlov; Sten Eirik W Jacobsen
Journal:  J Exp Med       Date:  2017-06-21       Impact factor: 14.307

View more
  20 in total

1.  First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.

Authors:  Stefanie Kreutmair; Dietmar Pfeifer; Miguel Waterhouse; Ferenc Takács; Linda Graessel; Konstanze Döhner; Justus Duyster; Anna Lena Illert; Anna-Verena Frey; Michael Schmitt; Michael Lübbert
Journal:  Cancer Immunol Immunother       Date:  2022-04-27       Impact factor: 6.630

2.  Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.

Authors:  Anica M Wandler; Benjamin J Huang; Jeffrey W Craig; Kathryn Hayes; Hannah Yan; Lauren K Meyer; Alessandro Scacchetti; Gabriela Monsalve; Monique Dail; Qing Li; Jasmine C Wong; Olga Weinberg; Robert P Hasserjian; Scott C Kogan; Philip Jonsson; Keith Yamamoto; Deepak Sampath; Joy Nakitandwe; James R Downing; Jinghui Zhang; Jon C Aster; Barry S Taylor; Kevin Shannon
Journal:  Leukemia       Date:  2020-02-17       Impact factor: 11.528

3.  Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.

Authors:  Laura K Schmalbrock; Anna Dolnik; Sibylle Cocciardi; Eric Sträng; Frauke Theis; Nikolaus Jahn; Ekaterina Panina; Tamara J Blätte; Julia Herzig; Sabrina Skambraks; Frank G Rücker; Verena I Gaidzik; Peter Paschka; Walter Fiedler; Helmut R Salih; Gerald Wulf; Thomas Schroeder; Michael Lübbert; Richard F Schlenk; Felicitas Thol; Michael Heuser; Richard A Larson; Arnold Ganser; Hendrik G Stunnenberg; Saverio Minucci; Richard M Stone; Clara D Bloomfield; Hartmut Döhner; Konstanze Döhner; Lars Bullinger
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

4.  14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.

Authors:  Danika Di Giacomo; Roberta La Starza; Paolo Gorello; Fabrizia Pellanera; Zeynep Kalender Atak; Kim De Keersmaecker; Valentina Pierini; Christine J Harrison; Silvia Arniani; Martina Moretti; Nicoletta Testoni; Giovanna De Santis; Giovanni Roti; Caterina Matteucci; Renato Bassan; Peter Vandenberghe; Stein Aerts; Jan Cools; Beat Bornhauser; Jean-Pierre Bourquin; Rocco Piazza; Cristina Mecucci
Journal:  Blood       Date:  2021-09-02       Impact factor: 22.113

Review 5.  RNA-Binding Proteins in Acute Leukemias.

Authors:  Konstantin Schuschel; Matthias Helwig; Stefan Hüttelmaier; Dirk Heckl; Jan-Henning Klusmann; Jessica I Hoell
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

6.  TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.

Authors:  Silvia Maifrede; Bac Viet Le; Margaret Nieborowska-Skorska; Konstantin Golovine; Katherine Sullivan-Reed; Wangisa M B Dunuwille; Joseph Nacson; Michael Hulse; Kelsey Keith; Jozef Madzo; Lisa Beatrice Caruso; Zachary Gazze; Zhaorui Lian; Antonella Padella; Kumaraswamy N Chitrala; Boris A Bartholdy; Ksenia Matlawska-Wasowska; Daniela Di Marcantonio; Giorgia Simonetti; Georg Greiner; Stephen M Sykes; Peter Valent; Elisabeth M Paietta; Martin S Tallman; Hugo F Fernandez; Mark R Litzow; Mark D Minden; Jian Huang; Giovanni Martinelli; George S Vassiliou; Italo Tempera; Katarzyna Piwocka; Neil Johnson; Grant A Challen; Tomasz Skorski
Journal:  Cancer Res       Date:  2021-07-02       Impact factor: 13.312

7.  WT1 inhibits AML cell proliferation in a p53-dependent manner.

Authors:  Yiyun Yao; Xingxing Chai; Chen Gong; Lifang Zou
Journal:  Cell Cycle       Date:  2021-07-21       Impact factor: 5.173

8.  Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice.

Authors:  Colleen E Annesley; Cara Rabik; Amy S Duffield; Rachel E Rau; Daniel Magoon; Li Li; Vicki Huff; Donald Small; David M Loeb; Patrick Brown
Journal:  Oncotarget       Date:  2018-10-19

Review 9.  Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.

Authors:  Cristina Panuzzo; Elisabetta Signorino; Chiara Calabrese; Muhammad Shahzad Ali; Jessica Petiti; Enrico Bracco; Daniela Cilloni
Journal:  J Clin Med       Date:  2020-03-16       Impact factor: 4.241

10.  Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient.

Authors:  Qiang Ma; Yixian Guo; Xiaoxi Lan; Guoxiang Wang; Wanling Sun
Journal:  BMC Med Genomics       Date:  2021-06-13       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.